Welcome to the e-CCO Library!

Page: () 1 2 3 4 5 6 7 8 9 10 ()
OP034: Efficacy and safety of abrilumab in subjects with Moderate to Severe Ulcerative Colitis: Results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Reinisch W.
Last Modified: Wednesday, 15 March 2017, 2:04 PM by ECCO Administrator
Abrilumab
Files: 1
OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations
Year: 2018
Source: ECCO'18 Vienna
Authors: Walker Gareth
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for Moderate to Severe Crohn’s Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Reinisch W.
Last Modified: Wednesday, 15 March 2017, 2:03 PM by ECCO Administrator
Abrilumab
Files: 1
OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with Inflammatory Bowel Disease: A nationwide cohort study
Year: 2018
Source: ECCO'18 Vienna
Authors: de Jong Michiel
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP036: Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild- moderately active Ulcerative Colitis: A randomised controlled trial
Year: 2017
Source: ECCO'17 Barcelona
Authors: Costello S.
Last Modified: Wednesday, 15 March 2017, 1:55 PM by ECCO Administrator
Microbiota, Faecal microbiota transplantation, environmental factors
Files: 1
OP037: Infants born to mothers with Inflammatory Bowel Disease exhibit distinct microbiome features that persist up to 3 months of life
Year: 2017
Source: ECCO'17 Barcelona
Authors: Torres J.
Last Modified: Wednesday, 15 March 2017, 1:56 PM by ECCO Administrator
Microbiota, IBD in pregnancy, environmental factors
Files: 1
OP038: Impact of ileocecal resection in Crohn’s Disease patients on mucosal microbiota
Year: 2017
Source: ECCO'17 Barcelona
Authors: Machiels K.
Last Modified: Wednesday, 15 March 2017, 1:52 PM by ECCO Administrator
Microbiota, Natural history, Ileo caecal resection
Files: 1
Opening
Year: 2018
Source: ECCO'18 Vienna
Authors: Panés Julián
Created: Friday, 23 March 2018, 12:23 PM
Outcomes from the 2015-2016 Fellowships: Hypoxia, antophagy and inflammasome
Year: 2017
Source: ECCO'17 Barcelona
Authors: Cosín J.
Last Modified: Wednesday, 15 March 2017, 2:35 PM by ECCO Administrator
environmental factors, Autophagy, Inflammosomes
Files: 1
Outcomes from the 2015-2016 Fellowships: Post-genomic application in general, and the establishment of computational approaches relevant to translational medicine
Year: 2017
Source: ECCO'17 Barcelona
Authors: Bonfiglio F.
Last Modified: Wednesday, 15 March 2017, 2:44 PM by ECCO Administrator
Croh's disease, Ulcerative colitis, Genetics
Files: 1
Pathogenesis of fistulising IBD
Year: 2018
Source: ECCO'18 Vienna
Authors: Scharl Michael
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
Patient perspective on treatment goals
Year: 2018
Source: ECCO'18 Vienna
Authors: Siegel Corey
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
Patient Reported Outcomes
Year: 2018
Source: 6th ClinCom Workshop
Authors: Peyrin-Biroulet Laurent
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
Perform endoscopy and IBD incl. chromo-endoscopy, balloon dilatation
Year: 2017
Source: 15th IBD Intensive Advanced Course
Authors: Michetti P., Ferrante M.
Last Modified: Wednesday, 15 March 2017, 1:31 PM by Vesna Babaja
stricture dilatation
Files: 1
Personalised medicine: Dream or reality?
Year: 2017
Source: ECCO'17 Barcelona
Authors: Dotan I.
Last Modified: Wednesday, 15 March 2017, 1:56 PM by ECCO Administrator
Predicting outcome
Files: 1
Pharmacoepidemiological studies on IBD using national registries. Examples from France
Year: 2018
Source: 4th EpiCom Workshop
Authors: Beaugerie Laurent
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
Pharmacoepidemiology of distinct populations: a focus on ageing and ethnic populations
Year: 2018
Source: 4th EpiCom Workshop
Authors: Arebi Naila
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
Placing new molecules in the treatment pathway
Year: 2017
Source: ECCO'17 Barcelona
Authors: Rogler G.
Last Modified: Wednesday, 15 March 2017, 1:46 PM by ECCO Administrator
Anti-TNF agents, Ustekinumab, Vedolizumab
Files: 1
Page: () 1 2 3 4 5 6 7 8 9 10 ()